But the sales bump did little to change the company’s bottom line, as net losses remained unchanged from the same period last year.
Overall, the Lawrence-based portable dialysis maker reported a $12.5 million loss on $36.4 million in sales, compared to a $12.5 million loss on $31.6 million for the same period last year. Excluding a $2 million charge to terminate the company’s credit facility with GE in June, NxStage would have beaten its previously announced guidance of net losses of $11.5 million to $12.5 million.
Predictably, the company’s home use dialysis products showed the strongest signs of growth during the quarter, jumping 28 percent from the same period last year.
The home market segment posted sales of $15.2 million, compared to $11.9 million for the same period last year, and is now on par with the company’s in-center business, which posted $16 million in sales, a 4 percent increase from last year.
NxStage’s critical care business also saw double-digit growth, posting $5.2 million in sales, a 20 percent increase from the same period last year.
Guidance for the year remains unchanged, as officials maintained predictions of revenues between $135 million to $145 million and a net loss in the range of $42 million to $47 million. For the third quarter, the company says it will likely post net losses in the range of $10 million to $11 million on about $32 million to $34.5 million in sales.